LG Chem announces plan to develop innovative therapy for renal cell carcinoma.

On November 5th, LG Chem announced that its anti-cancer drug development company AVEO has reached a collaboration agreement with the American biotech company HiberCell, signing a global exclusive research and development agreement for the Phase I clinical trial drug HC-5404. Through this agreement, LG Chem will introduce the kidney cancer treatment "FOTIVDA" and a new drug substance that is expected to have synergistic effects, officially launching a new treatment plan. Under the agreement, LG Chem will directly conduct Phase Ib clinical trials and decide in Phase II clinical trials whether to sign an agreement to ensure exclusive global licensing for the relevant substances.